Registry update — unassessed
Effect of Rapamycin in Ovarian Aging
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
RCTRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Dec 26, 2025 · Discovered: Sep 19, 2026 · Assessed: — · Historical research backfill
What it does not prove
- This abstract does not report any human findings and therefore does not establish whether rapamycin affects ovarian aging in women
- The study's design, sample size, primary outcome, and actual results are not described in the abstract provided
- No comparison of rapamycin to placebo outcomes is presented
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Women
- Primary outcome
- Ability of low-dose rapamycin to delay ovarian aging in women
- Effect size
- —
- Significance
- Not reported
- Journal
- Columbia University
- Published
- Dec 26, 2025
Sources
Primary source
- Columbia University ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
The investigators are proposing a prospective, randomized, double-blind, placebo-controlled pilot study assessing the ability of low-dose rapamycin to delay ovarian aging in women.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.